Literature DB >> 19225893

Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release.

Xiuling Lu1, Melissa D Howard, Dominique R Talbert, John J Rinehart, Philip M Potter, Michael Jay, Markos Leggas.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19225893      PMCID： PMC2664887          DOI： 10.1208/s12248-009-9086-3

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


× No keyword cloud information.
  11 in total

Review 1.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.

Authors:  S M Moghimi; J Szebeni
Journal:  Prog Lipid Res       Date:  2003-11       Impact factor: 16.195

Review 2.  Enzymes involved in the bioconversion of ester-based prodrugs.

Authors:  Bianca M Liederer; Ronald T Borchardt
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

3.  Reduction in carboplatin hematopoietic toxicity in tumor bearing mice: comparative mechanisms and effects of interleukin-1 beta and corticosteroids.

Authors:  J J Rinehart; L R Keville
Journal:  Cancer Biother Radiopharm       Date:  1997-04       Impact factor: 3.099

4.  Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.

Authors:  Bianca M Liederer; Ronald T Borchardt
Journal:  J Pharm Sci       Date:  2005-10       Impact factor: 3.534

5.  The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.

Authors:  C L Morton; R M Wadkins; M K Danks; P M Potter
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

6.  Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates.

Authors:  Huaizhong Pan; Pavla Kopecková; Jihua Liu; Dong Wang; Scott C Miller; Jindrich Kopecek
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

7.  Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization.

Authors:  Xiuling Lu; Melissa D Howard; Marta Mazik; Joshua Eldridge; John J Rinehart; Michael Jay; Markos Leggas
Journal:  AAPS J       Date:  2008-03-04       Impact factor: 4.009

8.  Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.

Authors:  Hui Wang; Mao Li; John J Rinehart; Ruiwen Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2004-01-30       Impact factor: 3.333

9.  Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.

Authors:  Markos Leggas; Kuei-Ling Kuo; Francisco Robert; Gretchen Cloud; Mollie deShazo; Ruiwen Zhang; Mao Li; Hui Wang; Steve Davidson; John Rinehart
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-24       Impact factor: 3.333

10.  Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.

Authors:  Hui Wang; Mao Li; John J Rinehart; Ruiwen Zhang
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531
View more
  4 in total

1.  High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery.

Authors:  Jin-Ki Kim; Hong Yuan; Jingxin Nie; Yu-Tsai Yang; Markos Leggas; Philip M Potter; John Rinehart; Michael Jay; Xiuling Lu
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

Review 2.  Nanocarriers for vascular delivery of anti-inflammatory agents.

Authors:  Melissa D Howard; Elizabeth D Hood; Blaine Zern; Vladimir V Shuvaev; Tilo Grosser; Vladimir R Muzykantov
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

3.  Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.

Authors:  Xinpeng Ma; Xiumei Huang; Zachary Moore; Gang Huang; Jessica A Kilgore; Yiguang Wang; Suntrea Hammer; Noelle S Williams; David A Boothman; Jinming Gao
Journal:  J Control Release       Date:  2014-12-24       Impact factor: 11.467

4.  Increased Body Exposure to New Anti-Trypanosomal Through Nanoencapsulation.

Authors:  Renata Tupinambá Branquinho; Gwenaelle Pound-Lana; Matheus Marques Milagre; Dênia Antunes Saúde-Guimarães; José Mário Carneiro Vilela; Margareth Spangler Andrade; Marta de Lana; Vanessa Carla Furtado Mosqueira
Journal:  Sci Rep       Date:  2017-08-16       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.